Constitutional trisomy 8 as first mutation in multistep carcinogenesis: Clinical, cytogenetic, and molecular data on three cases

Laura Seghezzi, Emanuela Maserati, Antonella Minelli, Claudia Dellavecchia, Paola Addis, Franco Locatelli, Adriano Angioni, Pietro Balloni, Crescenzo Miano, Pietro Cavalli, Cesare Danesino, Francesco Pasquali

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Three patients, with constitutional trisomy 8 mosaicism (CT8M), who developed a malignancy are reported. The diagnoses were refractory anaemia, acute lymphoblastic leukaemia, and idiopathic myelofibrosis. In the child with acute leukaemia, the CT8M was diagnosed at birth due to severe dysmorphisms and malformations; the other two patients showed a milder phenotype, and the CT8M was diagnosed only after the finding of trisomy 8 in neoplastic cells. The review of eight similar, previously reported cases and the clinical, cytogenetic, and molecular studies performed in our patients led us to make the following observations: (1) CT8M predisposes to neoplasms, preferentially to myelo- or lymphoproliferative diseases; (2) a gene dosage effect for glutathione reductase in red blood cells was seen in two of our patients; (3) the wide phenotypic variation of CT8M was confirmed: trisomy 8 in neoplastic cells of phenotypically near-normal cases may be misinterpreted as acquired; and (4) molecular studies suggested a postzygotic origin of the trisomy in our three cases, with the supernumerary chromosome being of paternal origin in one case and of maternal origin in the other two. We postulate that the trisomy 8 in neoplasms may often occur by mitotic nondisjunction in an early embryonic multipotent cell and that what is usually interpreted as an acquired trisomy 8 may in fact be CT8M. The constitutional trisomy 8 would act as a pathogenetically important first mutation in multistep carcinogenesis. Whenever trisomy 8 is found in malignancies, the patient should be reevaluated clinically to exclude CT8M, and CT8M patients should be monitored for the possible development of malignancies.

Original languageEnglish
Pages (from-to)94-101
Number of pages8
JournalGenes Chromosomes and Cancer
Volume17
Issue number2
DOIs
Publication statusPublished - Oct 1996

Fingerprint

Cytogenetics
Carcinogenesis
Mutation
Neoplasms
Refractory Anemia
Primary Myelofibrosis
Gene Dosage
Mosaic trisomy Chromosome 8
Trisomy Chromosome 8
Glutathione Reductase
Trisomy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
Chromosomes
Erythrocytes
Mothers
Parturition
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Constitutional trisomy 8 as first mutation in multistep carcinogenesis : Clinical, cytogenetic, and molecular data on three cases. / Seghezzi, Laura; Maserati, Emanuela; Minelli, Antonella; Dellavecchia, Claudia; Addis, Paola; Locatelli, Franco; Angioni, Adriano; Balloni, Pietro; Miano, Crescenzo; Cavalli, Pietro; Danesino, Cesare; Pasquali, Francesco.

In: Genes Chromosomes and Cancer, Vol. 17, No. 2, 10.1996, p. 94-101.

Research output: Contribution to journalArticle

Seghezzi, Laura ; Maserati, Emanuela ; Minelli, Antonella ; Dellavecchia, Claudia ; Addis, Paola ; Locatelli, Franco ; Angioni, Adriano ; Balloni, Pietro ; Miano, Crescenzo ; Cavalli, Pietro ; Danesino, Cesare ; Pasquali, Francesco. / Constitutional trisomy 8 as first mutation in multistep carcinogenesis : Clinical, cytogenetic, and molecular data on three cases. In: Genes Chromosomes and Cancer. 1996 ; Vol. 17, No. 2. pp. 94-101.
@article{97265d78e6ca45fb9bc63b4b7e69f002,
title = "Constitutional trisomy 8 as first mutation in multistep carcinogenesis: Clinical, cytogenetic, and molecular data on three cases",
abstract = "Three patients, with constitutional trisomy 8 mosaicism (CT8M), who developed a malignancy are reported. The diagnoses were refractory anaemia, acute lymphoblastic leukaemia, and idiopathic myelofibrosis. In the child with acute leukaemia, the CT8M was diagnosed at birth due to severe dysmorphisms and malformations; the other two patients showed a milder phenotype, and the CT8M was diagnosed only after the finding of trisomy 8 in neoplastic cells. The review of eight similar, previously reported cases and the clinical, cytogenetic, and molecular studies performed in our patients led us to make the following observations: (1) CT8M predisposes to neoplasms, preferentially to myelo- or lymphoproliferative diseases; (2) a gene dosage effect for glutathione reductase in red blood cells was seen in two of our patients; (3) the wide phenotypic variation of CT8M was confirmed: trisomy 8 in neoplastic cells of phenotypically near-normal cases may be misinterpreted as acquired; and (4) molecular studies suggested a postzygotic origin of the trisomy in our three cases, with the supernumerary chromosome being of paternal origin in one case and of maternal origin in the other two. We postulate that the trisomy 8 in neoplasms may often occur by mitotic nondisjunction in an early embryonic multipotent cell and that what is usually interpreted as an acquired trisomy 8 may in fact be CT8M. The constitutional trisomy 8 would act as a pathogenetically important first mutation in multistep carcinogenesis. Whenever trisomy 8 is found in malignancies, the patient should be reevaluated clinically to exclude CT8M, and CT8M patients should be monitored for the possible development of malignancies.",
author = "Laura Seghezzi and Emanuela Maserati and Antonella Minelli and Claudia Dellavecchia and Paola Addis and Franco Locatelli and Adriano Angioni and Pietro Balloni and Crescenzo Miano and Pietro Cavalli and Cesare Danesino and Francesco Pasquali",
year = "1996",
month = "10",
doi = "10.1002/(SICI)1098-2264(199610)17:2<94::AID-GCC4>3.0.CO;2-W",
language = "English",
volume = "17",
pages = "94--101",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Constitutional trisomy 8 as first mutation in multistep carcinogenesis

T2 - Clinical, cytogenetic, and molecular data on three cases

AU - Seghezzi, Laura

AU - Maserati, Emanuela

AU - Minelli, Antonella

AU - Dellavecchia, Claudia

AU - Addis, Paola

AU - Locatelli, Franco

AU - Angioni, Adriano

AU - Balloni, Pietro

AU - Miano, Crescenzo

AU - Cavalli, Pietro

AU - Danesino, Cesare

AU - Pasquali, Francesco

PY - 1996/10

Y1 - 1996/10

N2 - Three patients, with constitutional trisomy 8 mosaicism (CT8M), who developed a malignancy are reported. The diagnoses were refractory anaemia, acute lymphoblastic leukaemia, and idiopathic myelofibrosis. In the child with acute leukaemia, the CT8M was diagnosed at birth due to severe dysmorphisms and malformations; the other two patients showed a milder phenotype, and the CT8M was diagnosed only after the finding of trisomy 8 in neoplastic cells. The review of eight similar, previously reported cases and the clinical, cytogenetic, and molecular studies performed in our patients led us to make the following observations: (1) CT8M predisposes to neoplasms, preferentially to myelo- or lymphoproliferative diseases; (2) a gene dosage effect for glutathione reductase in red blood cells was seen in two of our patients; (3) the wide phenotypic variation of CT8M was confirmed: trisomy 8 in neoplastic cells of phenotypically near-normal cases may be misinterpreted as acquired; and (4) molecular studies suggested a postzygotic origin of the trisomy in our three cases, with the supernumerary chromosome being of paternal origin in one case and of maternal origin in the other two. We postulate that the trisomy 8 in neoplasms may often occur by mitotic nondisjunction in an early embryonic multipotent cell and that what is usually interpreted as an acquired trisomy 8 may in fact be CT8M. The constitutional trisomy 8 would act as a pathogenetically important first mutation in multistep carcinogenesis. Whenever trisomy 8 is found in malignancies, the patient should be reevaluated clinically to exclude CT8M, and CT8M patients should be monitored for the possible development of malignancies.

AB - Three patients, with constitutional trisomy 8 mosaicism (CT8M), who developed a malignancy are reported. The diagnoses were refractory anaemia, acute lymphoblastic leukaemia, and idiopathic myelofibrosis. In the child with acute leukaemia, the CT8M was diagnosed at birth due to severe dysmorphisms and malformations; the other two patients showed a milder phenotype, and the CT8M was diagnosed only after the finding of trisomy 8 in neoplastic cells. The review of eight similar, previously reported cases and the clinical, cytogenetic, and molecular studies performed in our patients led us to make the following observations: (1) CT8M predisposes to neoplasms, preferentially to myelo- or lymphoproliferative diseases; (2) a gene dosage effect for glutathione reductase in red blood cells was seen in two of our patients; (3) the wide phenotypic variation of CT8M was confirmed: trisomy 8 in neoplastic cells of phenotypically near-normal cases may be misinterpreted as acquired; and (4) molecular studies suggested a postzygotic origin of the trisomy in our three cases, with the supernumerary chromosome being of paternal origin in one case and of maternal origin in the other two. We postulate that the trisomy 8 in neoplasms may often occur by mitotic nondisjunction in an early embryonic multipotent cell and that what is usually interpreted as an acquired trisomy 8 may in fact be CT8M. The constitutional trisomy 8 would act as a pathogenetically important first mutation in multistep carcinogenesis. Whenever trisomy 8 is found in malignancies, the patient should be reevaluated clinically to exclude CT8M, and CT8M patients should be monitored for the possible development of malignancies.

UR - http://www.scopus.com/inward/record.url?scp=10544255084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10544255084&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2264(199610)17:2<94::AID-GCC4>3.0.CO;2-W

DO - 10.1002/(SICI)1098-2264(199610)17:2<94::AID-GCC4>3.0.CO;2-W

M3 - Article

C2 - 8913726

AN - SCOPUS:10544255084

VL - 17

SP - 94

EP - 101

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

IS - 2

ER -